Stock listing
Shanghai:688177 Bio-Thera Solutions, Ltd. (百奥泰) 股价
Follow Bio-Thera Solutions, Ltd. into a list and get an email when it puts out news.
Share price · SSE:688177
¥14.16 CNY -0.87 (-5.8%)
Close on Nov 20, 2026
- Day range
- ¥14.15 – ¥14.69 CNYNov 20, 2026
- Volume
- 2.98M sharesNov 20, 2026
- Market cap
- ¥5.86B CNYAt the close on Nov 20, 2026 · price × 414.1M shares outstanding
- 52-week range
- ¥14.15 – ¥26.33 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥68.64M CNYMedian day 3.19M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688177 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥14.16 | -0.87 | -5.8% | ¥14.69 | ¥14.69 | ¥14.15 | 2,977,983 | |
| ¥15.03 | -0.59 | -3.8% | ¥15.73 | ¥15.79 | ¥15.02 | 2,542,438 | |
| ¥15.62 | -0.54 | -3.3% | ¥16.10 | ¥16.35 | ¥15.53 | 3,471,826 | |
| ¥16.16 | -0.56 | -3.3% | ¥16.55 | ¥16.75 | ¥16.01 | 2,677,568 | |
| ¥16.72 | -0.59 | -3.4% | ¥17.35 | ¥17.40 | ¥16.61 | 2,035,224 | |
| ¥17.31 | -0.35 | -2.0% | ¥17.66 | ¥17.70 | ¥17.31 | 2,429,102 | |
| ¥17.66 | +0.13 | +0.7% | ¥17.61 | ¥17.73 | ¥17.40 | 1,564,935 | |
| ¥17.53 | -0.11 | -0.6% | ¥17.88 | ¥18.03 | ¥17.53 | 1,522,984 | |
| ¥17.64 | -0.13 | -0.7% | ¥17.98 | ¥18.11 | ¥17.51 | 1,928,892 | |
| ¥17.77 | -0.05 | -0.3% | ¥17.57 | ¥18.07 | ¥17.36 | 3,314,094 | |
| ¥17.82 | +0.51 | +2.9% | ¥17.31 | ¥17.99 | ¥17.31 | 3,096,081 | |
| ¥17.31 | +0.74 | +4.5% | ¥16.51 | ¥17.55 | ¥16.35 | 4,262,133 | |
| ¥16.57 | -0.25 | -1.5% | ¥16.89 | ¥16.89 | ¥16.32 | 3,402,348 | |
| ¥16.82 | +0.46 | +2.8% | ¥16.37 | ¥17.00 | ¥16.07 | 3,475,183 | |
| ¥16.36 | -0.57 | -3.4% | ¥16.65 | ¥17.68 | ¥16.26 | 4,184,419 | |
| ¥16.93 | -0.43 | -2.5% | ¥17.37 | ¥17.43 | ¥16.60 | 3,343,422 | |
| ¥17.36 | +0.08 | +0.5% | ¥17.55 | ¥17.80 | ¥16.89 | 2,908,470 | |
| ¥17.28 | -0.73 | -4.1% | ¥18.20 | ¥18.29 | ¥17.28 | 2,493,119 | |
| ¥18.01 | -0.10 | -0.6% | ¥18.01 | ¥18.39 | ¥17.83 | 2,599,894 | |
| ¥18.11 | +0.77 | +4.4% | ¥17.21 | ¥18.20 | ¥16.76 | 3,823,585 | |
| ¥17.34 | -0.45 | -2.5% | ¥18.05 | ¥18.15 | ¥17.27 | 2,557,006 | |
| ¥17.79 | -0.10 | -0.6% | ¥18.10 | ¥18.48 | ¥17.75 | 2,926,401 | |
| ¥17.89 | +0.70 | +4.1% | ¥17.30 | ¥17.91 | ¥16.91 | 3,488,053 | |
| ¥17.19 | +0.26 | +1.5% | ¥17.00 | ¥17.47 | ¥16.64 | 3,227,266 | |
| ¥16.93 | -0.16 | -0.9% | ¥17.25 | ¥17.94 | ¥16.79 | 3,730,956 | |
| ¥17.09 | -0.34 | -2.0% | ¥17.22 | ¥17.93 | ¥17.00 | 4,336,998 | |
| ¥17.43 | -0.48 | -2.7% | ¥17.77 | ¥17.98 | ¥17.20 | 2,919,829 | |
| ¥17.91 | -0.80 | -4.3% | ¥18.60 | ¥18.63 | ¥17.55 | 3,666,043 | |
| ¥18.71 | -0.59 | -3.1% | ¥19.50 | ¥19.52 | ¥18.68 | 3,341,419 | |
| ¥19.30 | +0.07 | +0.4% | ¥19.06 | ¥19.84 | ¥18.46 | 5,585,575 | |
| ¥19.23 | -1.80 | -8.6% | ¥20.68 | ¥21.60 | ¥19.10 | 5,485,175 | |
| ¥21.03 | +0.82 | +4.1% | ¥20.01 | ¥21.34 | ¥20.01 | 4,997,608 | |
| ¥20.21 | -0.44 | -2.1% | ¥20.45 | ¥20.87 | ¥20.00 | 4,488,138 | |
| ¥20.65 | -0.18 | -0.9% | ¥20.80 | ¥21.36 | ¥20.21 | 4,947,856 | |
| ¥20.83 | -0.44 | -2.1% | ¥21.51 | ¥21.68 | ¥20.77 | 7,173,494 | |
| ¥21.27 | +0.17 | +0.8% | ¥21.00 | ¥21.93 | ¥20.81 | 10,792,189 | |
| ¥21.10 | +1.74 | +9.0% | ¥19.36 | ¥21.34 | ¥19.06 | 11,476,537 | |
| ¥19.36 | +2.16 | +12.6% | ¥17.31 | ¥19.55 | ¥17.20 | 9,841,286 | |
| ¥17.20 | +0.46 | +2.7% | ¥16.77 | ¥17.42 | ¥16.77 | 2,975,913 | |
| ¥16.74 | +0.15 | +0.9% | ¥16.60 | ¥16.96 | ¥16.41 | 1,891,200 | |
| ¥16.59 | +0.13 | +0.8% | ¥16.50 | ¥16.63 | ¥16.27 | 1,537,424 | |
| ¥16.46 | -0.36 | -2.1% | ¥16.80 | ¥16.85 | ¥16.41 | 1,601,982 | |
| ¥16.82 | +0.58 | +3.6% | ¥16.30 | ¥16.89 | ¥16.03 | 2,724,874 | |
| ¥16.24 | -0.53 | -3.2% | ¥16.81 | ¥16.84 | ¥16.01 | 2,818,767 | |
| ¥16.77 | -0.30 | -1.8% | ¥17.01 | ¥17.09 | ¥16.59 | 1,741,301 | |
| ¥17.07 | -0.34 | -2.0% | ¥17.40 | ¥17.40 | ¥17.01 | 1,856,320 | |
| ¥17.41 | +0.14 | +0.8% | ¥17.54 | ¥17.55 | ¥17.06 | 2,341,364 | |
| ¥17.27 | -0.21 | -1.2% | ¥17.50 | ¥17.62 | ¥17.23 | 1,938,659 | |
| ¥17.48 | -0.31 | -1.7% | ¥17.84 | ¥17.95 | ¥17.42 | 2,835,834 | |
| ¥17.79 | +0.14 | +0.8% | ¥17.67 | ¥17.90 | ¥17.51 | 2,313,675 | |
| ¥17.65 | -0.16 | -0.9% | ¥17.81 | ¥17.87 | ¥17.35 | 2,978,402 | |
| ¥17.81 | -0.40 | -2.2% | ¥18.17 | ¥18.30 | ¥17.69 | 4,606,051 | |
| ¥18.21 | -0.42 | -2.3% | ¥18.63 | ¥18.63 | ¥18.09 | 3,160,230 | |
| ¥18.63 | -0.11 | -0.6% | ¥18.60 | ¥19.04 | ¥18.39 | 3,542,970 | |
| ¥18.74 | -0.66 | -3.4% | ¥19.39 | ¥19.39 | ¥18.38 | 5,028,825 | |
| ¥19.40 | -0.74 | -3.7% | ¥19.99 | ¥20.98 | ¥19.29 | 3,883,621 | |
| ¥20.14 | +0.17 | +0.9% | ¥19.97 | ¥20.23 | ¥19.57 | 2,955,815 | |
| ¥19.97 | -0.74 | -3.6% | ¥20.60 | ¥20.88 | ¥19.80 | 3,459,189 | |
| ¥20.71 | -1.04 | -4.8% | ¥21.32 | ¥21.75 | ¥20.61 | 4,869,704 | |
| ¥21.75 | +1.18 | +5.7% | ¥21.58 | ¥22.35 | ¥20.88 | 8,087,524 |
- Ticker
- Shanghai:688177
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Shanghai
- Currency
- CNY
What changed lately
Latest news release · Nov 17, 2026
(688177)"Bio-Thera Solutions, Ltd."Notice on Convening the 4th Extraordinary General Meeting in 2026
Latest news
(688177)"Bio-Thera Solutions, Ltd."Notice on Convening the 4th Extraordinary General Meeting in 2026
Nov 17, 2026
Closed ¥15.62 (-3.3%) on Nov 17, 2026
(688177)"Bio-Thera Solutions, Ltd."Announcement on Change of Accounting Firm
Nov 17, 2026
Closed ¥15.62 (-3.3%) on Nov 17, 2026
(688177)"Bio-Thera Solutions, Ltd."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
Nov 14, 2026
Closed ¥16.16 (-3.3%) on Nov 16, 2026
(688177)"Bio-Thera Solutions, Ltd."Announcement on Obtaining a Drug Registration Certificate for Ashuli (Golimumab Injection)
Nov 6, 2026
Closed ¥17.77 (-0.3%) on Nov 6, 2026
(688177)"Bio-Thera Solutions, Ltd."Announcement on the Latest Business Development of BAT1706 (Bevacizumab)
Nov 3, 2026
Closed ¥16.57 (-1.5%) on Nov 3, 2026
(688177)"Bio-Thera Solutions, Ltd."Announcement on Convening the Q3 2026 Performance Briefing
Nov 3, 2026
Closed ¥16.57 (-1.5%) on Nov 3, 2026
(688177)"Bio-Thera Solutions, Ltd."Report for Q3 2026
Oct 28, 2026
Closed ¥17.36 (+0.5%) on Oct 28, 2026
(688177)"Bio-Thera Solutions, Ltd."Notice on Convening the 3rd Extraordinary General Meeting in 2026
Oct 28, 2026
Closed ¥17.36 (+0.5%) on Oct 28, 2026
Bio-Thera Solutions, Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 50 in the last 12 months · 107 in all · newest Nov 17, 2026 · oldest 2023
Valuation
EV/sales 5.9× against a median of 26.0×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥6.17B CNY
- P/E
- Loss
- EV/sales
- 5.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 137×
- Gross margin
- 81.0%
- Operating margin
- −39.2%
- Net margin
- −42.0%
- Debt to equity
- 14.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Bio-Thera Solutions, Ltd. Class A · SSE:688177 | US$880.1M | US$926.3M | n/a | 5.9× | n/a | 137× | −42.0% | 14.3× | n/a |
| MoonLake Immunotherapeutics · NASDAQ:MLTX | US$942.1M | US$543.7M | n/a | n/a | n/a | 2.5× | n/a | 0.3× | 1.32 |
| Savara, Inc. · NASDAQ:SVRA | US$939.9M | US$840.4M | n/a | n/a | n/a | 8.7× | n/a | 0.3× | 1.42 |
| Metis TechBio Co., Ltd. Class H · HKEX:7666 | US$918.2M | US$486.7M | n/a | 222× | n/a | 2.0× | −373.2% | 0.0× | n/a |
| InventisBio, Co., Ltd. Class A · SSE:688382 | US$899.5M | US$714.3M | n/a | 67.0× | n/a | 4.6× | −533.7% | 0.0× | n/a |
| InnoCare Pharma Ltd. Class A · SSE:688428 | US$896.7M | −US$209.5M | 9.3× | −0.6× | −2.3× | 0.8× | 27.1% | 0.1× | n/a |
| Immatics N.V. · NASDAQ:IMTX | US$878.3M | US$375.4M | n/a | 7.9× | n/a | 1.8× | −534.1% | 0.0× | 1.40 |
| Suzhou Ribo Life Science Co. Ltd. Class H · HKEX:6938 | US$875.5M | US$580.0M | n/a | 26.0× | n/a | 3.4× | −187.2% | 0.2× | n/a |
| Aktis Oncology, Inc. · NASDAQ:AKTS | US$868.0M | US$385.9M | n/a | 31.2× | n/a | 1.9× | −706.8% | 0.0× | 1.21 |
| Latigo Biotherapeutics, Inc. · NASDAQ:LTGO | US$861.9M | US$460.7M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Pharming Group NV · EURONEXT:PHARM | US$840.1M | US$766.3M | 34.4× | 2.0× | 19.8× | 2.9× | 6.3% | 0.4× | n/a |
| Median of the others | US$887.5M | US$515.2M | 21.9× | 26.0× | 8.7× | 2.3× | −373.2% | 0.1× | 1.36 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 26.30 CNY · Analysts' mean
- EPS, year to Dec 2026
- -0.83 · 1 analyst
- Revenue, year to Dec 2026
- 1.28B · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Susan Ringdal | EVP, Strategic Planning and Global Affairs |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2022 | Apr 29, 2022 · Before open | −6.6% |
| Q4 2021 | Mar 4, 2022 · Before open | −0.8% |
| Q3 2021 | Oct 29, 2021 | +0.5% |
| Quarter to Jun 30, 2021 | Aug 27, 2021 | +8.9% |
| Quarter to Mar 31, 2021 | Apr 28, 2021 | −6.4% |
| Quarter to Dec 31, 2020 | Mar 4, 2021 · Before open | −1.7% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 935.2M | 743.2M | 704.8M | 455.1M | 836.6M | 185.0M | 700.0K | 0 | 2.01M | 2.76M |
| Cost of revenue | 197.2M | 229.5M | 193.3M | 190.6M | 35.6M | 19.9M | 127.8K | 722.7K | 1.92M | |
| Gross profit | 738.0M | 513.6M | 511.5M | 264.5M | 801.0M | 165.1M | 572.3K | 0 | 1.29M | 842.0K |
| Research and development | 800.2M | 777.6M | 768.6M | 616.4M | 543.4M | 562.7M | 636.5M | 541.7M | 236.5M | 131.5M |
| Selling, general and administrative | 273.3M | 215.5M | 102.8M | 153.7M | 194.4M | 143.2M | 32.6M | 8.94M | 5.82M | 4.81M |
| Operating income | -346.3M | -496.0M | -392.6M | -494.6M | 84.3M | -546.6M | -1.02B | -553.7M | -239.1M | -143.6M |
| Depreciation and amortization | 104.3M | 89.4M | 85.2M | 83.8M | 72.9M | 59.0M | 55.5M | 49.5M | 23.0M | 5.23M |
| EBITDA | -242.0M | -406.6M | -307.3M | -410.8M | 157.2M | -487.7M | -969.3M | -504.2M | -216.1M | -138.4M |
| Interest expense | 20.1M | 20.6M | 10.4M | 61.9K | 775.4K | 3.70M | 770.0K | 27.8K | 0 | 0 |
| Income before tax | -331.6M | -510.3M | -394.4M | -480.4M | 91.0M | -513.2M | -1.02B | -553.1M | -235.5M | -136.6M |
| Income tax | 2.13K | 9.11M | ||||||||
| Net income | -331.9M | -510.3M | -394.5M | -480.4M | 81.9M | -513.2M | -1.02B | -553.1M | -235.5M | -136.6M |
| Earnings per share, basic | -0.80 | -1.23 | -0.95 | -1.16 | 0.20 | -1.24 | -2.89 | -1.56 | -0.67 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 218.6M | 289.8M | 164.0M | 165.9M | 847.5M | 283.5M | 39.1M | 112.4M | 33.4M | 8.42M |
| Short-term investments | 90.2M | 331.0M | 629.9M | 602.8M | 955.8M | |||||
| Receivables | 164.7M | 104.1M | 148.7M | 89.8M | 103.3M | 55.4M | 1.11M | 986.2K | 11.0M | 2.25M |
| Inventory | 312.4M | 253.1M | 231.2M | 161.9M | 90.1M | 45.9M | 43.6M | 36.7M | 7.87M | 2.14M |
| Current assets | 958.6M | 888.0M | 1.01B | 1.16B | 1.77B | 1.47B | 177.8M | 217.3M | 120.8M | 332.2M |
| Property, plant and equipment | 693.9M | 579.4M | 581.7M | 425.4M | 417.9M | 427.4M | 300.2M | |||
| Total assets | 2.29B | 2.21B | 2.29B | 2.18B | 2.62B | 2.39B | 1.01B | 1.02B | 618.9M | 708.3M |
| Accounts payable | 198.7M | 199.5M | 171.5M | 83.8M | 45.7M | 84.8M | 153.5M | 99.1M | 111.4M | 116.2M |
| Current liabilities | 1.37B | 1.10B | 725.4M | 538.5M | 526.0M | 385.4M | 380.5M | 213.2M | 271.0M | 173.3M |
| Long-term debt | 374.2M | 370.4M | 323.8M | 3.00M | ||||||
| Total liabilities | 1.91B | 1.50B | 1.07B | 572.5M | 530.3M | 387.6M | 383.7M | 219.4M | 271.4M | 173.9M |
| Shareholders' equity | 376.0M | 708.1M | 1.21B | 1.61B | 2.09B | 2.01B | 630.7M | 801.3M | 347.6M | 534.4M |
| Shares outstanding | 414.1M | 414.1M | 414.1M | 414.1M | 414.1M | 414.1M | 354.1M | 354.1M | 354.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -82.1M | -55.7M | -460.9M | -412.8M | 236.3M | -358.0M | -598.0M | -528.2M | -236.7M | -116.2M |
| Capital spending | -121.7M | -126.8M | -275.9M | -258.8M | -77.9M | -253.3M | -74.8M | -317.8M | -160.8M | -119.2M |
| Free cash flow | -203.9M | -182.5M | -780.3M | -671.6M | 158.4M | -611.3M | -672.8M | -846.0M | -397.5M | -235.4M |
| Cash from investing | -245.8M | 301.8M | -1.18B | -74.8M | -339.3M | -145.6M | -119.1M | |||
| Cash from financing | -30.2M | 26.5M | 1.78B | 599.3M | 933.0M | 99.0M | ||||
| Dividends paid | -20.4M | -20.6M | -5.67M | -164.5K | -553.0K | -3.85M | -620.6K | -620.6K | -620.6K | |
| Change in cash | -50.1M | 150.9M | 169.4M | -688.0M | 563.8M | 244.2M | -73.5M | 65.4M | -283.2M | 311.4M |
Filings
All 75 filings
Cap table
Built by 6ix from Bio-Thera Solutions, Ltd. Class A’s releases
- Common shares
- 414,080,000
- Fully diluted
- 414,080,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 414,080,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 414,080,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Susan Ringdal | EVP, Strategic Planning and Global Affairs · Since at least May 27, 2025 |
Log in to ask 6ix AI your own questions about Bio-Thera Solutions, Ltd.